Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat a phase 2 pilot study. En savoir plus sur Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat a phase 2 pilot study.
Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux. En savoir plus sur Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux.